IRIDEX Corporation (IRIX) |
| 1.15 -0.02 (-1.71%) 06-03 15:44 |
| Open: | 1.16 |
| High: | 1.19 |
| Low: | 1.1358 |
| Volume: | 88,451 |
| Market Cap: | 20(M) |
| PE Ratio: | -6.05 |
| Exchange: | NASDAQ Global Market |
| Industry: | Medical - Devices |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 1.40 |
| Resistance 1: | 1.20 |
| Pivot price: | 1.05 |
| Support 1: | 1.06 |
| Support 2: | 0.98 |
| 52w High: | 1.65 |
| 52w Low: | 0.87 |
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.
| EPS | -0.190 |
| Book Value | -0.070 |
| PEG Ratio | 0.94 |
| Gross Profit | 1.086 |
| Profit Margin (%) | -6.23 |
| Operating Margin (%) | -2.75 |
| Return on Assets (ttm) | -5.4 |
| Return on Equity (ttm) | -56.5 |
Wed, 03 Jun 2026
Iridex CFO Romeo Dizon buys $2,808 in company stock - Investing.com
Wed, 03 Jun 2026
CFO of IRIDEX (NASDAQ: IRIX) purchases 2,400 company shares - Stock Titan
Mon, 25 May 2026
IRIX Stock Up 4% As Q1 Loss Narrows Y/Y on Glaucoma Product Growth - Yahoo Finance
Wed, 20 May 2026
IRIDEX Corporation (NASDAQ:IRIX) Q1 2026 Earnings Call Transcript - Insider Monkey
Wed, 20 May 2026
IRIDEX Corp (IRIX) Q1 2026 Earnings Call Highlights: Navigating Challenges with Strategic Growth Initiatives - GuruFocus
Tue, 19 May 2026
Is IRIDEX (IRIX) a Value Trap After Q1 2026? EPS -$0.03 Beats (e - GuruFocus
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |